| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions (NCT02091908) | Seqirus | 2014-04-01 |
| Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya (NCT01810731) | Centers for Disease Control and Prevention | 2014-04-01 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine (NCT02107807) | Seqirus | 2014-04-01 |
| Treatment of Severe Influenza A Infection (NCT02108366) | The University of Hong Kong | 2014-03-01 |
| Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group. (NCT02101749) | Mahidol University | 2013-11-01 |
| Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents (NCT02621177) | SK Chemicals Co., Ltd. | 2013-11-01 |
| MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine (NCT02225327) | Korea University Guro Hospital | 2013-10-01 |
| Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults (NCT01967368) | The University of Hong Kong | 2013-10-01 |
| Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects (NCT02344134) | SK Chemicals Co., Ltd. | 2013-09-01 |
| A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers (NCT01863433) | Seqirus | 2013-05-01 |
| A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers (NCT01857297) | Seqirus | 2013-05-01 |
| Evaluating Modes of Influenza Transmission (NCT01710111) | University of Nottingham | 2013-01-01 |
| Influenza Vaccine and Pneumococcal Vaccine (NCT02582047) | Korea University Guro Hospital | 2012-10-01 |
| Jet Injection for Influenza (NCT01688921) | PharmaJet, Inc. | 2012-10-01 |
| DNA-based Influenza Vaccine in the Elderly (NCT01587131) | University of Manitoba | 2012-06-01 |
| A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers (NCT01591837) | Seqirus | 2012-05-01 |
| Safety Study of FluMist With and Without Ampligen (NCT01591473) | AIM ImmunoTech Inc. | 2012-04-01 |
| Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge (NCT02755948) | Imperial College London | 2012-04-01 |
| A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection (NCT01527110) | GlaxoSmithKline | 2012-01-01 |
| Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o. (NCT03206346) | Valenta Pharm JSC | 2012-01-01 |
| Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza (NCT01390025) | Theraclone Sciences, Inc. | 2011-09-01 |
| Persistence of Immune Response After Vaccination With Influenza Vaccine (NCT01906190) | Centers for Disease Control and Prevention, China | 2011-08-01 |
| Safety of Inhaled Zanamivir in Pregnancy (NCT01462487) | GlaxoSmithKline | 2011-07-01 |
| A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers (NCT01353729) | GlaxoSmithKline | 2011-05-19 |
| Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (NCT01314911) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-04-01 |
| A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (NCT01231620) | GlaxoSmithKline | 2011-01-15 |
| Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males (NCT01428479) | GlaxoSmithKline | 2011-01-07 |
| Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults (NCT01369862) | AVIR Green Hills Biotechnology AG | 2011-01-01 |
| A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers (NCT01258530) | GlaxoSmithKline | 2010-12-20 |
| Field Trial of Maternal Influenza Immunization in Asia (NCT01034254) | Children's Hospital Medical Center, Cincinnati | 2010-11-01 |
| Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections (NCT03189537) | Valenta Pharm JSC | 2010-10-03 |
| Clinical Validation of the Point-of-Care MSD Influenza Test (NCT00863343) | Meso Scale Diagnostics, LLC. | 2010-03-01 |
| Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults (NCT03154515) | Valenta Pharm JSC | 2010-01-01 |
| Oseltamivir Infant Influenza Safety Study (NCT01286142) | Charite University, Berlin, Germany | 2009-12-01 |
| Dose Finding Study of Single Dose GHB11L1 in Healthy Adults (NCT01078701) | AVIR Green Hills Biotechnology AG | 2009-12-01 |
| Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital (NCT01014988) | GlaxoSmithKline | 2009-11-01 |
| Relenza® Sentinel Site Monitoring Program in Japan (NCT01199744) | GlaxoSmithKline | 2009-11-01 |
| VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years (NCT00995982) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-10-08 |
| Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents (NCT01407978) | Fluart Innovative Vaccine Ltd, Hungary | 2009-08-01 |
| Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years (NCT00929331) | GlaxoSmithKline | 2009-07-11 |
| Prophylactic Efficacy of Relenza Against Influenza A and B (NCT01156701) | GlaxoSmithKline | 2009-07-01 |
| VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat... (NCT00858611) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-03-03 |
| Face Masks for Preventing Influenza Transmission (NCT00774774) | Assistance Publique - Hôpitaux de Paris | 2009-01-01 |
| A Multinational Phase III Study of CS-8958 (MARVEL) (NCT00803595) | Daiichi Sankyo Co., Ltd. | 2008-11-01 |
| Vaccine for Prevention of Bird Flu (NCT00776711) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-10-16 |
| A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. (NCT00545532) | Hoffmann-La Roche | 2008-02-04 |
| Revaccination With Influenza Vaccine GSK1247446A (NCT00545025) | GlaxoSmithKline | 2007-10-15 |
| A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines (NCT00558649) | NanoPass Technologies Ltd | 2007-05-01 |
| Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis) (NCT01390792) | GlaxoSmithKline | 2007-01-01 |
| Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus (NCT02950688) | National Institute of Allergy and Infectious Diseases (NIAID) | |